24 March 2016 - Consideration is currently being given to a codeine rescheduling proposal to up-schedule to Schedule 4 (S4) low dose codeine containing products currently available as S2 and S3 medicines.

To support this work, the TGA commissioned an independent review of the safety and efficacy of low dose codeine containing products. The Review was undertaken by Dr Christina Abdel Shaheed and Professor Chris Maher of the George Institute and Professor Andrew McLachlan of the University of Sydney.

For more details, go to: http://www.tga.gov.au/alert/review-efficacy-and-safety-over-counter-codeine-combination-medicines